NCT02846623View on ClinicalTrials.gov

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

PHASE2RecruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Chronic Lymphocytic LeukemiaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaRichter SyndromeSmall Lymphocytic Lymphoma
Interventions
DRUG

Atezolizumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Obinutuzumab

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER